These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

485 related items for PubMed ID: 19405528

  • 1. Potent cytotoxic C-11 modified geldanamycin analogues.
    Tian ZQ, Wang Z, MacMillan KS, Zhou Y, Carreras CW, Mueller T, Myles DC, Liu Y.
    J Med Chem; 2009 May 28; 52(10):3265-73. PubMed ID: 19405528
    [Abstract] [Full Text] [Related]

  • 2. Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90.
    Sydor JR, Normant E, Pien CS, Porter JR, Ge J, Grenier L, Pak RH, Ali JA, Dembski MS, Hudak J, Patterson J, Penders C, Pink M, Read MA, Sang J, Woodward C, Zhang Y, Grayzel DS, Wright J, Barrett JA, Palombella VJ, Adams J, Tong JK.
    Proc Natl Acad Sci U S A; 2006 Nov 14; 103(46):17408-13. PubMed ID: 17090671
    [Abstract] [Full Text] [Related]

  • 3. Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90.
    Ge J, Normant E, Porter JR, Ali JA, Dembski MS, Gao Y, Georges AT, Grenier L, Pak RH, Patterson J, Sydor JR, Tibbitts TT, Tong JK, Adams J, Palombella VJ.
    J Med Chem; 2006 Jul 27; 49(15):4606-15. PubMed ID: 16854066
    [Abstract] [Full Text] [Related]

  • 4. Synthesis and anticancer activity of geldanamycin derivatives derived from biosynthetically generated metabolites.
    Lee K, Ryu JS, Jin Y, Kim W, Kaur N, Chung SJ, Jeon YJ, Park JT, Bang JS, Lee HS, Kim TY, Lee JJ, Hong YS.
    Org Biomol Chem; 2008 Jan 21; 6(2):340-8. PubMed ID: 18175003
    [Abstract] [Full Text] [Related]

  • 5. Effects of Hsp90 inhibition in neuroblastoma: analysis of drug sensitivity, target modulation and the influence of bone marrow microenvironment.
    Jayanthan A, Fowler J, Hawkins L, Lamers F, Teja B, Incoronato A, Anderson R, Narendran A.
    J Exp Ther Oncol; 2008 Jan 21; 7(3):183-93. PubMed ID: 19066127
    [Abstract] [Full Text] [Related]

  • 6. Anti-proliferative activity of heat shock protein (Hsp) 90 inhibitors via beta-catenin/TCF7L2 pathway in adult T cell leukemia cells.
    Kurashina R, Ohyashiki JH, Kobayashi C, Hamamura R, Zhang Y, Hirano T, Ohyashiki K.
    Cancer Lett; 2009 Oct 18; 284(1):62-70. PubMed ID: 19464103
    [Abstract] [Full Text] [Related]

  • 7. The Hsp90 inhibitor 17-allylamide-17-demethoxygeldanamycin induces apoptosis and differentiation of Kasumi-1 harboring the Asn822Lys KIT mutation and down-regulates KIT protein level.
    Yu W, Rao Q, Wang M, Tian Z, Lin D, Liu X, Wang J.
    Leuk Res; 2006 May 18; 30(5):575-82. PubMed ID: 16213582
    [Abstract] [Full Text] [Related]

  • 8. Molecular characterization of macbecin as an Hsp90 inhibitor.
    Martin CJ, Gaisser S, Challis IR, Carletti I, Wilkinson B, Gregory M, Prodromou C, Roe SM, Pearl LH, Boyd SM, Zhang MQ.
    J Med Chem; 2008 May 08; 51(9):2853-7. PubMed ID: 18357975
    [Abstract] [Full Text] [Related]

  • 9. Synthesis and biological evaluation of a new class of geldanamycin derivatives as potent inhibitors of Hsp90.
    Le Brazidec JY, Kamal A, Busch D, Thao L, Zhang L, Timony G, Grecko R, Trent K, Lough R, Salazar T, Khan S, Burrows F, Boehm MF.
    J Med Chem; 2004 Jul 15; 47(15):3865-73. PubMed ID: 15239664
    [Abstract] [Full Text] [Related]

  • 10. Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models.
    Banerji U, Walton M, Raynaud F, Grimshaw R, Kelland L, Valenti M, Judson I, Workman P.
    Clin Cancer Res; 2005 Oct 01; 11(19 Pt 1):7023-32. PubMed ID: 16203796
    [Abstract] [Full Text] [Related]

  • 11. Rituximab and 17-allylamino-17-demethoxygeldanamycin induce synergistic apoptosis in B-cell chronic lymphocytic leukaemia.
    Johnson AJ, Wagner AJ, Cheney CM, Smith LL, Lucas DM, Guster SK, Grever MR, Lin TS, Byrd JC.
    Br J Haematol; 2007 Dec 01; 139(5):837-44. PubMed ID: 17949452
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo.
    Schwock J, Pham NA, Cao MP, Hedley DW.
    Cancer Chemother Pharmacol; 2008 Apr 01; 61(4):669-81. PubMed ID: 17579866
    [Abstract] [Full Text] [Related]

  • 13. Immune expression and inhibition of heat shock protein 90 in uveal melanoma.
    Faingold D, Marshall JC, Antecka E, Di Cesare S, Odashiro AN, Bakalian S, Fernandes BF, Burnier MN.
    Clin Cancer Res; 2008 Feb 01; 14(3):847-55. PubMed ID: 18245548
    [Abstract] [Full Text] [Related]

  • 14. Design, synthesis and biological evaluation of 17-arylmethylamine-17-demethoxygeldanamycin derivatives as potent Hsp90 inhibitors.
    Li Z, Jia L, Wang J, Wu X, Hao H, Xu H, Wu Y, Shi G, Lu C, Shen Y.
    Eur J Med Chem; 2014 Oct 06; 85():359-70. PubMed ID: 25105924
    [Abstract] [Full Text] [Related]

  • 15. Discovery and development of heat shock protein 90 inhibitors as anticancer agents: a review of patented potent geldanamycin derivatives.
    Kim T, Keum G, Pae AN.
    Expert Opin Ther Pat; 2013 Aug 06; 23(8):919-43. PubMed ID: 23641970
    [Abstract] [Full Text] [Related]

  • 16. Geldanamycin and 17-allylamino-17-demethoxygeldanamycin potentiate the in vitro and in vivo radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signaling and cytotoxicity.
    Bisht KS, Bradbury CM, Mattson D, Kaushal A, Sowers A, Markovina S, Ortiz KL, Sieck LK, Isaacs JS, Brechbiel MW, Mitchell JB, Neckers LM, Gius D.
    Cancer Res; 2003 Dec 15; 63(24):8984-95. PubMed ID: 14695217
    [Abstract] [Full Text] [Related]

  • 17. Mechanistic studies on Hsp90 inhibition by ansamycin derivatives.
    Onuoha SC, Mukund SR, Coulstock ET, Sengerovà B, Shaw J, McLaughlin SH, Jackson SE.
    J Mol Biol; 2007 Sep 14; 372(2):287-97. PubMed ID: 17662999
    [Abstract] [Full Text] [Related]

  • 18. Conformational significance of EH21A1-A4, phenolic derivatives of geldanamycin, for Hsp90 inhibitory activity.
    Onodera H, Kaneko M, Takahashi Y, Uochi Y, Funahashi J, Nakashima T, Soga S, Suzuki M, Ikeda S, Yamashita Y, Rahayu ES, Kanda Y, Ichimura M.
    Bioorg Med Chem Lett; 2008 Mar 01; 18(5):1588-91. PubMed ID: 18243703
    [Abstract] [Full Text] [Related]

  • 19. Synthesis and biological activities of novel 17-aminogeldanamycin derivatives.
    Tian ZQ, Liu Y, Zhang D, Wang Z, Dong SD, Carreras CW, Zhou Y, Rastelli G, Santi DV, Myles DC.
    Bioorg Med Chem; 2004 Oct 15; 12(20):5317-29. PubMed ID: 15388159
    [Abstract] [Full Text] [Related]

  • 20. Dihydroquinone ansamycins: toward resolving the conflict between low in vitro affinity and high cellular potency of geldanamycin derivatives.
    Maroney AC, Marugan JJ, Mezzasalma TM, Barnakov AN, Garrabrant TA, Weaner LE, Jones WJ, Barnakova LA, Koblish HK, Todd MJ, Masucci JA, Deckman IC, Galemmo RA, Johnson DL.
    Biochemistry; 2006 May 02; 45(17):5678-85. PubMed ID: 16634649
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.